Genentech is a biotechnology company that discovers, develops, manufactures, and commercializes medicines to treat patients with serious or life-threatening medical conditions. It creates multiple products on the market and a development pipeline. The company became a member of the Roche Group in 2009. As part of their merger agreement, Roche and Genentech combined their pharmaceutical operations in the United States. Genentech’s South San Francisco campus now serves as the headquarters for Roche pharmaceutical operations in the United States. Genentech’s Research and Early Development section operates as an independent center within Roche. Genentech was founded in 1976 by [Robert Swanson](https://www.crunchbase.com/person/robert-a-swanson) and [Herbert Boyer](https://www.crunchbase.com/person/herbert-w-boyer). It is headquartered in South San Francisco, C.A.

F. Hoffmann-La Roche Ltd. manufactures pharmaceutical products. It offers pharmaceutical drugs, pharmaceutical instruments, and diagnostics solutions. The company was founded by Fritz Hoffmann-La Roche on October 1, 1896 and is headquartered in Basel, Switzerland.

NantOmics develops cloud-based molecular profiling tools that help guide cancer patients. It is a molecular diagnostics company, develops molecular profiling solutions that identify personalized treatment options for cancer patients and their providers at the point of care. It offers GPS Cancer test that provides a molecular profile of patient’s cancer to inform personalized treatment strategies to oncologists and OncoPlexDx Targeted Proteomic panel that provides quantitative protein biomarker information for multiple clinically relevant proteins yielding insights into the biology driving the growth of the patient’s cancer. Patrick Soon-Shiong founded NantOmics in 2012, with its headquarters in Culver City, California. NantOmics operates as a subsidiary of NantWorks.

NATCO Pharma Ltd. engages in the business of pharmaceuticals with research, manufacturing and marketing of finished dosage formulations and active pharmaceutical ingredients. It operates through the following segments: Domestic Formulations, International Formulations, and Active Pharmaceutical Ingredients. The Domestic Formulations segment operates in the divisions of oncology, pharma specialties and CnD. The International Formulations segment exports its FDF products from India to several international geographies either through its local partners or directly through its subsidiaries such as in Canada and Brazil. The Active Pharmaceutical Ingredients segment is strategically important as it develops APIs for the captive consumption of many of NATCO's critical FDF products in addition to supplying to direct customers. The company was founded by Venkaiah Chowdary Nannapaneni in 1981 and is headquartered in Hyderabad, India.

Seattle Genetics is a clinical-stage biotechnology company that focuses on developing and commercializing monoclonal antibody-based therapies for the treatment of cancer and autoimmune diseases. Its lead product, SGN-35, is in the pivotal trial for patients with relapsed or refractory Hodgkin lymphoma. The company's other product candidates in various stages of clinical trials include dacetuzumab (SGN-40), a humanized anti-CD40 antibody; lintuzumab (SGN-33), a humanized anti-CD33 antibody; SGN-70, a humanized anti-CD70 antibody for the treatment of autoimmune diseases; SGN-75, which is in Phase I clinical trials for metastatic renal cell carcinoma and non-Hodgkin lymphoma; ASG-5ME, a preclinical antibody-drug conjugate product candidate for the treatment of solid tumors; and SGN-19A, a preclinical antibody-drug conjugate product candidate for the treatment of hematologic malignancies. It has collaborations with Bayer Pharmaceuticals Corporation; Celldex Therapeutics, Inc.; Daiichi Sankyo Co., Ltd.; Genentech; GlaxoSmithKline LLC; MedImmune, Inc.; Millennium; PSMA Development Company LLC; and Genmab A/S. The company also has an antibody-drug conjugates co-development agreement with Agensys, Inc. The company was founded in 1997 and is headquartered in Bothell, Washington.

Relay Therapeutics, Inc. engages in transforming the drug discovery process with an initial focus on enhancing small molecule therapeutic discovery in targeted oncology. Its Dynamo platform is use to integrate an array of edge experimental and computational approaches, which allows to apply the understanding of protein structure and motion to drug discovery. The company was founded by David Elliot Shaw, Matthew P. Jacobson, Dorothee Kern, Mark Murcko, Alexis Borisy, and Jakob Loven on May 4, 2015 and is headquartered in Cambridge, MA.

D. E. Shaw Research ("DESRES") is engaged in scientific research and technological development in the field of computational biochemistry, including - The design of novel algorithms and machine architectures for high-speed molecular dynamics (MD) simulations of proteins and other biological macromolecules. In particular, they have designed and constructed a specialized supercomputer called Anton, which executes such simulations orders of magnitude faster than was previously possible, along with a number of software tools and techniques that facilitate their execution and analysis. - The use of long MD simulations to study the structural changes underlying biological phenomena that occur on time scales far in excess of those previously accessible to computational study, with the ultimate aim of significantly advancing the process of drug discovery. They have been investigating, for example, the mechanisms of certain cellular receptors, transport proteins, and enzymes relevant to the understanding and potential treatment of cancer, diabetes, and other diseases. Their research team includes computational chemists and biologists, computer scientists and applied mathematicians, and computer architects and engineers, all working collaboratively under the leadership of its chief scientist, David Shaw.

Nanjing Kaifu Biotechnology Co., Ltd., established on 2019-03-26, Business scope includes biotechnology,Medical technology research and development,technology transfer,Technical Services,technical consulting;R&D and sales of medical devices;Development and sales of diagnostic kits.(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments)

OncoPlexDx is a CLIA-certified cancer diagnostics laboratory in Rockville, MD that provides clinical proteomics for patient care. By quantitating proteins, It provide information that helps physicians choose targeted therapies and avoid therapies that won’t work.

Roche Products Ltd. manufactures diagnostic, diabetes, and pharmaceutical products. The company was founded on December 14, 1908 and is headquartered in Welwyn Garden City, the United Kingdom.

GTx, Inc. is a a biopharmaceutical company, which engages in the discovery, development, and commercialization of small molecules for the treatment of muscle-related diseases and other serious medical conditions. It focuses on developing selective androgen receptor modulators and selective androgen receptor degrader for the treatment of breast cancer, stress urinary incontinence, Duchenne muscular dystrophy, and prostate cancer. The company was founded by Marc Steven Hanover and Mitchell Shuster Steiner on September 24, 1997 and is headquartered in Memphis, TN.

The University of California is the nation's best public university system, delivering top-notch research and innovation to California (and the world).

Shamu (Shanghai) Biotechnology Co., Ltd., established on 2016-11-29, The scope of business includes engaging in biotechnology,Technology development in the field of medical technology,technical consulting,Technical Services,Business Management Consulting,Nutrition and Health Consulting Services,Special packaging equipment,laboratory equipment,Clean equipment,Optical Instruments,beauty equipment,Ι class medical device,Daily necessities,Sports Equipment,Fitness Equipment,Chemical raw materials and products(Removal of hazardous chemicals,Monitor Chemicals,firecrackers,civilian explosives,precursor chemicals),plastic products,Electrical Equipment,Wujinjiaodian,Instrument sales. [Items subject to approval by law,Business activities can only be carried out after approval by relevant departments]

Chongqing Kerun Biomedical R&D Co., Ltd. was established in 1997, formerly known as Chongqing Rainwater Group Duotai Biomedical Research Institute, focusing on the research and development of recombinant protein drugs. After nearly two decades of development, the company has established a mature yeast expression technology platform and E. coli expression technology platform, and is currently actively building a mammalian cell expression platform. A drug development system with specifications from options, upstream construction, protein expression, process development, quality control, and registration declarations.

Kosan Biosciences Incorporated, a cancer therapeutics company, focuses on developing various classes of anticancer agents through clinical development. Its product KOS-953, a Hsp90 inhibitor is in Phase III clinical trial in combination with Velcade for multiple myeloma, as well as in Phase II clinical trial in combination with Herceptin for HER2-positive metastatic breast cancer. The company's product portfolio also includes KOS-1584, an epothilone anticancer product candidate evaluated in dose-escalating Phase I clinical trial in patients with solid tumors; KOS-1803, a preclinical stage product for cancer; KOS-2187, a potent motilin receptor agonist that is in Phase I clinical testing for the treatment of GERD. In addition, Kosan Biosciences develops KOS-2464, a preclinical stage product for cancer. The company was founded in 1995 and is based in Hayward, California. As of June 25, 2008, Kosan Biosciences Incorporated operates as a subsidiary of Bristol-Myers Squibb Co.

Shanghai Companion Medical Technology Co., Ltd., established on 2018-01-15, The scope of business includes engaging in biotechnology,Technology development in the field of medical science and technology,technical consulting,Technical Services,technology transfer,Own Equipment Rental,Research and development of pharmaceutical intermediates,Research and development of biological reagents for non-clinical diagnosis,Sales,Sales of instrumentation,Medical device management,Engaged in the import and export of goods and technology. [Items subject to approval by law,Business activities can only be carried out after approval by relevant departments]

Suzhou GenePharma Co.,Ltd. engages in the manufacture of biotechnology products. Its products cover chemically-synthetic RNA monomer, custom siRNA oligo, chemically-modified RNA oligo, fluorescent dye for biological macromolecules marker; Biosynthesis siRNA, shRNA; DNAs encoding shRNA, plasmid vector encoding shRNA; RNAi service based on chemical synthesis, RNAi service based on vector regulation; siRNA related reagents and RNA-related product sales; common molecular biology reagent and laboratory supplies sales. The company was founded on August 27, 2007 and is headquartered in Shanghai, China.